Accéder au contenu
Merck

Comparison of intranasal and intravenous diazepam on status epilepticus in stroke patients: a retrospective cohort study.

Medicine (2015-02-24)
Ryota Inokuchi, Naoko Ohashi-Fukuda, Kensuke Nakamura, Tomoki Wada, Masataka Gunshin, Yoichi Kitsuta, Susumu Nakajima, Naoki Yahagi
RÉSUMÉ

Administering diazepam intravenously or rectally in an adult with status epilepticus can be difficult and time consuming. The aim of this study was to examine whether intranasal diazepam is an effective alternative to intravenous diazepam when treating status epilepticus. We undertook a retrospective cohort study based on the medical records of 19 stroke patients presenting with status epilepticus to our institution. We measured the time between arrival at the hospital, the intravenous or intranasal administration of diazepam, and the seizure termination. Intranasal diazepam was administered about 9 times faster than intravenous diazepam (1 vs 9.5 minutes, P = 0.001), resulting in about 3-fold reduction in the time to termination of seizure activity after arrival at the hospital (3 minutes compared with 9.5 minutes in the intravenous group, P = 0.030). No adverse effects of intranasal diazepam were evident from the medical records. Intranasal diazepam administration is safer, easier, and quicker than intravenous administration.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Diazepam
Supelco
Diazepam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Diazepam, European Pharmacopoeia (EP) Reference Standard
Diazepam for system suitability, European Pharmacopoeia (EP) Reference Standard